NCT04417621 2026-03-12
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
Novartis
Phase 2 Active not recruiting
Novartis
Erasca, Inc.
Erasca, Inc.
Novartis
Novartis
Novartis
Novartis
Boehringer Ingelheim
Novartis
Amgen
Deciphera Pharmaceuticals, LLC